LOS ANGELES - The U.S. Food and Drug Administration on Monday expanded emergency use authorization for Pfizer-BioNTech’s COVID-19 vaccine in the United States for older children ages 12 to 15.Last month, Pfizer said Phase 3 clinical trials found its COVID-19 vaccine was safe and 100% effective among this age group.
The preliminary data showed there were no cases among the fully vaccinated adolescents compared to 18 among those given placebo shots.The study involved 2,260 U.S.
volunteers ages 12 to 15 and has not yet been peer-reviewed.Overall, kids develop a serious illness or die from COVID-19 at much lower rates than adults, but they do still get sick and can spread the virus.Children make up roughly 13% of COVID-19 cases that have been.